HomeCompareINKM vs JNJ

INKM vs JNJ: Dividend Comparison 2026

INKM yields 5.02% · JNJ yields 3.36%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 INKM wins by $7.8K in total portfolio value
10 years
INKM
INKM
● Live price
5.02%
Share price
$33.52
Annual div
$1.68
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$27.8K
Annual income
$691.63
Full INKM calculator →
JNJ
Johnson & Johnson
● Live price
3.36%
Share price
$147.50
Annual div
$4.96
5Y div CAGR
5.8%
Payout ratio
55%
After 10 yrs · $10,000 · DRIP
Portfolio value
$20.0K
Annual income
$827.78
Full JNJ calculator →

Portfolio growth — INKM vs JNJ

📍 INKM pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodINKMJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, INKM + JNJ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
INKM pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

INKM
Annual income on $10K today (after 15% tax)
$426.49/yr
After 10yr DRIP, annual income (after tax)
$587.89/yr
JNJ
Annual income on $10K today (after 15% tax)
$285.83/yr
After 10yr DRIP, annual income (after tax)
$703.61/yr
At 15% tax rate, JNJ beats the other by $115.73/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of INKM + JNJ for your $10,000?

INKM: 50%JNJ: 50%
100% JNJ50/50100% INKM
Portfolio after 10yr
$23.9K
Annual income
$759.70/yr
Blended yield
3.18%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

INKM
No analyst data
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
+55.1% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

INKM buys
0
JNJ buys
0
No recent congressional trades found for INKM or JNJ in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricINKMJNJ
Forward yield5.02%3.36%
Annual dividend / share$1.68$4.96
Payout ratio50%55%
1-year div growth0%4.2%
5-year div CAGR0%5.8%
Portfolio after 10y$27.8K$20.0K
Annual income after 10y$691.63$827.78
Total dividends collected$6.0K$5.6K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: INKM vs JNJ ($10,000, DRIP)

YearINKM PortfolioINKM Income/yrJNJ PortfolioJNJ Income/yrGap
1← crossover$11,202$501.75$10,676$355.77+$526.00INKM
2$12,511$525.28$11,407$389.39+$1.1KINKM
3$13,935$548.30$12,198$426.53+$1.7KINKM
4$15,481$570.76$13,056$467.62+$2.4KINKM
5$17,158$592.61$13,987$513.12+$3.2KINKM
6$18,973$613.81$14,998$563.56+$4.0KINKM
7$20,935$634.33$16,098$619.52+$4.8KINKM
8$23,055$654.15$17,295$681.69+$5.8KINKM
9$25,342$673.25$18,599$750.82+$6.7KINKM
10$27,807$691.63$20,022$827.78+$7.8KINKM

INKM vs JNJ: Complete Analysis 2026

INKMStock

The State Street Income Allocation ETF seeks to provide total return by focusing on investment in income and yield-generating assetsActively managed fund that pursues total return, primarily through investing in asset classes that produce current incomeCombines tactical allocations among US government and corporate bonds; US convertible and preferred securities; global REITs; and domestic and international equities with a focus on dividendsTactical, active management presents opportunities to add value as markets change

Full INKM Calculator →

JNJHealthcare

Johnson & Johnson is a Dividend King with 62+ years of consecutive dividend increases. A healthcare conglomerate spanning pharmaceuticals, MedTech, and consumer health. JNJ spun off its consumer segment as Kenvue in 2023, focusing on higher-margin pharma and medical devices.

Full JNJ Calculator →
📬

Get this INKM vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

INKM vs SCHDINKM vs JEPIINKM vs OINKM vs KOINKM vs MAININKM vs ABBVINKM vs MRKINKM vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.